Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,exchangeDataDelayedBy,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,EPIX,199697583.0,39335600,6231908,,-8751211,,-8752011,3117900,0,-9349808,-9349808,,-16667,,,,800,0,9349808,0,598597,,-8752011,-8752011,33619332.0,3826462.0,199697583.0,203524045.0,277370996.0,188610.0,-109216266.0,597508.0,-2076479.0,268574.0,145194181.0,3008727.0,-2076479.0,297533.0,202957938.0,57068822.0,231146.0,907537.0,-9000,-113088,-11288,-9062,189178,37236,318229,-6368122,-28744,-6517268,25503,-2288,85503,-119989,2199589,199949211.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,2.205,18.246666,-8.597166,-0.47116366,26.10384,-16.45434,-0.63034177,379568864,4.3761907,15,America/New_York,EDT,-14400000,False,False,9.6495,1630509659,0.16950035,9.4,9.7,9.3475,131114,REGULAR,NCM,2,1.7879784,9.3475 - 9.7,9.48,9.63,9.69,8,8,finmb_275296588,NasdaqCM,ESSA Pharma Inc.,USD,569600,967583,4.2495,0.7869444,5.4 - 36.0,-26.3505,-0.7319583,5.4,36.0,1524614400,1613050200,1613050200,1613050200,-0.991,0,ESSA Pharma Inc.,1.65,,,36.0,5.4,18.25,26.1,569.6k,967.58k,39.34M,,27.39M,2.62%,82.28%,1.66M,2.99,4.79%,3.96%,972.5k,,,,,,0.00%,"Apr 24, 2018",,1:20,"Apr 24, 2018","Sep 29, 2020","Jun 29, 2021",0.00%,0.00%,-16.74%,-27.74%,,,,,,-32.8M,-0.99,,202.26M,4.6,317.99k,0.16,67.46,2.20,-22.18M,-9.91M,Value,V5Z 1K5,Healthcare,25,"ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.",Vancouver,778 331 0962,BC,1609372800,Canada,http://www.essapharma.com,86400,999 West Broadway,Biotechnology,Suite 720
t-1,EPIX,205408071.0,39335600,7268257,,-12965247,,-12965247,4615332,0,-11883589,-11883589,,-299,,,,0,0,11883589,0,-1081658,,-12965247,-12965247,31208296.0,4592983.0,205408071.0,210001054.0,276740509.0,115130.0,-100464255.0,1166462.0,-2076479.0,277637.0,151562303.0,3179691.0,-2076479.0,341125.0,209382292.0,57034921.0,293106.0,1690676.0,-35017103,1016047,-35003478,-30288,141637320,645761,150777070,99077791,16419,-7572470,27581,13625,-83062,-9109462,3786450,206202601.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,2.205,18.246666,-8.597166,-0.47116366,26.10384,-16.45434,-0.63034177,379568864,4.3761907,15,America/New_York,EDT,-14400000,False,False,9.6495,1630509659,0.16950035,9.4,9.7,9.3475,131114,REGULAR,NCM,2,1.7879784,9.3475 - 9.7,9.48,9.63,9.69,8,8,finmb_275296588,NasdaqCM,ESSA Pharma Inc.,USD,569600,967583,4.2495,0.7869444,5.4 - 36.0,-26.3505,-0.7319583,5.4,36.0,1524614400,1613050200,1613050200,1613050200,-0.991,0,ESSA Pharma Inc.,1.65,,,36.0,5.4,18.25,26.1,569.6k,967.58k,39.34M,,27.39M,2.62%,82.28%,1.66M,2.99,4.79%,3.96%,972.5k,,,,,,0.00%,"Apr 24, 2018",,1:20,"Apr 24, 2018","Sep 29, 2020","Jun 29, 2021",0.00%,0.00%,-16.74%,-27.74%,,,,,,-32.8M,-0.99,,202.26M,4.6,317.99k,0.16,67.46,2.20,-22.18M,-9.91M,Value,V5Z 1K5,Healthcare,25,"ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.",Vancouver,778 331 0962,BC,1609372800,Canada,http://www.essapharma.com,86400,999 West Broadway,Biotechnology,Suite 720
t-2,EPIX,74101365.0,39335600,4485772,,-6563853,,-6528704,2208917,0,-6694689,-6694689,,-1181,,,,-35149,0,6694689,0,130836,,-6528704,-6528704,29289327.0,2073623.0,74101365.0,76174988.0,134387525.0,122731.0,-87499008.0,38246.0,-2076479.0,277637.0,52484512.0,2035377.0,-2076479.0,,75897351.0,22016344.0,231191.0,1375781.0,-35017103,867841,-35003478,-30287,150932,462405,181219,-3836251,-44595,-3942588,27581,13625,102308,-9109462,1125981,73861974.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,2.205,18.246666,-8.597166,-0.47116366,26.10384,-16.45434,-0.63034177,379568864,4.3761907,15,America/New_York,EDT,-14400000,False,False,9.6495,1630509659,0.16950035,9.4,9.7,9.3475,131114,REGULAR,NCM,2,1.7879784,9.3475 - 9.7,9.48,9.63,9.69,8,8,finmb_275296588,NasdaqCM,ESSA Pharma Inc.,USD,569600,967583,4.2495,0.7869444,5.4 - 36.0,-26.3505,-0.7319583,5.4,36.0,1524614400,1613050200,1613050200,1613050200,-0.991,0,ESSA Pharma Inc.,1.65,,,36.0,5.4,18.25,26.1,569.6k,967.58k,39.34M,,27.39M,2.62%,82.28%,1.66M,2.99,4.79%,3.96%,972.5k,,,,,,0.00%,"Apr 24, 2018",,1:20,"Apr 24, 2018","Sep 29, 2020","Jun 29, 2021",0.00%,0.00%,-16.74%,-27.74%,,,,,,-32.8M,-0.99,,202.26M,4.6,317.99k,0.16,67.46,2.20,-22.18M,-9.91M,Value,V5Z 1K5,Healthcare,25,"ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.",Vancouver,778 331 0962,BC,1609372800,Canada,http://www.essapharma.com,86400,999 West Broadway,Biotechnology,Suite 720
t-3,EPIX,79243865.0,39335600,2236680,,-4567989,,-4553342,2200159,0,-4436839,-4436839,,-1181,,,,-14647,0,4436839,0,-131150,,-4553342,-4553342,31204284.0,1330700.0,79243865.0,80574565.0,131086364.0,179690.0,-80970304.0,127376.0,-2076479.0,277637.0,56320763.0,1203324.0,-2076479.0,,80296928.0,22011337.0,309538.0,678643.0,-22011337,36827,-21737252,-30288,45770865,-964813,48999308,19838714,-43917,-4150982,27581,274085,76967,-3198155,1223798,79093604.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,2.205,18.246666,-8.597166,-0.47116366,26.10384,-16.45434,-0.63034177,379568864,4.3761907,15,America/New_York,EDT,-14400000,False,False,9.6495,1630509659,0.16950035,9.4,9.7,9.3475,131114,REGULAR,NCM,2,1.7879784,9.3475 - 9.7,9.48,9.63,9.69,8,8,finmb_275296588,NasdaqCM,ESSA Pharma Inc.,USD,569600,967583,4.2495,0.7869444,5.4 - 36.0,-26.3505,-0.7319583,5.4,36.0,1524614400,1613050200,1613050200,1613050200,-0.991,0,ESSA Pharma Inc.,1.65,,,36.0,5.4,18.25,26.1,569.6k,967.58k,39.34M,,27.39M,2.62%,82.28%,1.66M,2.99,4.79%,3.96%,972.5k,,,,,,0.00%,"Apr 24, 2018",,1:20,"Apr 24, 2018","Sep 29, 2020","Jun 29, 2021",0.00%,0.00%,-16.74%,-27.74%,,,,,,-32.8M,-0.99,,202.26M,4.6,317.99k,0.16,67.46,2.20,-22.18M,-9.91M,Value,V5Z 1K5,Healthcare,25,"ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.",Vancouver,778 331 0962,BC,1609372800,Canada,http://www.essapharma.com,86400,999 West Broadway,Biotechnology,Suite 720
